These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 37660438

  • 1. Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial.
    Fizazi K, Shore ND, Smith M, Ramos R, Jones R, Niegisch G, Vjaters E, Wang Y, Srinivasan S, Sarapohja T, Verholen F.
    Eur J Cancer; 2023 Oct; 192():113258. PubMed ID: 37660438
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.
    Shore ND, Gratzke C, Feyerabend S, Werbrouck P, Carles J, Vjaters E, Tammela TLJ, Morris D, Aragon-Ching JB, Concepcion RS, Emmenegger U, Fleshner N, Grabbert M, Lietuvietis V, Mahammedi H, Cruz FM, Paula A, Pieczonka C, Rannikko A, Richardet M, Silveira G, Kuss I, Le Berre MA, Verholen F, Sarapohja T, Smith MR, Fizazi K.
    Oncologist; 2024 Jul 05; 29(7):581-588. PubMed ID: 38394384
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial.
    Shore N, Zurth C, Fricke R, Gieschen H, Graudenz K, Koskinen M, Ploeger B, Moss J, Prien O, Borghesi G, Petrenciuc O, Tammela TL, Kuss I, Verholen F, Smith MR, Fizazi K.
    Target Oncol; 2019 Oct 05; 14(5):527-539. PubMed ID: 31571095
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial.
    Smith MR, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Mohamed AF, Odom D, Bartsch J, Snapir A, Sarapohja T, Fizazi K.
    Eur J Cancer; 2021 Sep 05; 154():138-146. PubMed ID: 34273811
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of darolutamide in Black/African-American patients from the phase III ARAMIS study.
    Shore ND, Cruz F, Nordquist L, Belkoff L, Aronson WJ, Tolia B, Cinman A, Sharifi R, Ortiz J, Parkin J, Srinivasan S, Sarapohja T, Smith MR.
    Future Oncol; 2022 Dec 05; 18(40):4473-4482. PubMed ID: 36753353
    [Abstract] [Full Text] [Related]

  • 10. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
    Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR, ARAMIS Investigators.
    N Engl J Med; 2019 Mar 28; 380(13):1235-1246. PubMed ID: 30763142
    [Abstract] [Full Text] [Related]

  • 11. Darolutamide and survival in nonmetastatic, castration-resistant prostate cancer: a patient perspective of the ARAMIS trial.
    Fizazi K, Blue I, Nowak JT.
    Future Oncol; 2021 May 28; 17(14):1699-1707. PubMed ID: 33554636
    [Abstract] [Full Text] [Related]

  • 12. Impact of darolutamide on local symptoms: pre-planned and post hoc analyses of the ARAMIS trial.
    Shore ND, Stenzl A, Pieczonka C, Klaassen Z, Aronson WJ, Karsh L, Ryan CJ, Ortiz J, Srinivasan S, Mohamed AF, Verholen F.
    BJU Int; 2023 Apr 28; 131(4):452-460. PubMed ID: 36087070
    [Abstract] [Full Text] [Related]

  • 13. Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
    Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR, ARAMIS Investigators.
    N Engl J Med; 2020 Sep 10; 383(11):1040-1049. PubMed ID: 32905676
    [Abstract] [Full Text] [Related]

  • 14. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.
    Fizazi K, Smith MR, Tombal B.
    Clin Genitourin Cancer; 2018 Oct 10; 16(5):332-340. PubMed ID: 30197098
    [Abstract] [Full Text] [Related]

  • 15. Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.
    Scott LJ.
    Target Oncol; 2020 Dec 10; 15(6):791-799. PubMed ID: 33237495
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial.
    Shore ND, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford D, Tombal B, Nordquist L, Cookson M, Verholen F, Jhaveri J, Srinivasan S, Smith MR.
    Oncologist; 2024 Mar 04; 29(3):235-243. PubMed ID: 37812679
    [Abstract] [Full Text] [Related]

  • 17. Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.
    Hussain M, Tombal B, Saad F, Fizazi K, Sternberg CN, Crawford ED, Shore N, Kopyltsov E, Kalebasty AR, Bögemann M, Ye D, Cruz F, Suzuki H, Kapur S, Srinivasan S, Verholen F, Kuss I, Joensuu H, Smith MR.
    J Clin Oncol; 2023 Jul 10; 41(20):3595-3607. PubMed ID: 36795843
    [Abstract] [Full Text] [Related]

  • 18. The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: An Indirect Comparison.
    Shore N, Jiang S, Garcia-Horton V, Terasawa E, Steffen D, Chin A, Ayyagari R, Partridge J, Waldeck AR.
    Adv Ther; 2022 Nov 10; 39(11):5025-5042. PubMed ID: 36028656
    [Abstract] [Full Text] [Related]

  • 19. [Darolutamide: A new drug for non-metastatic castration-resistant prostate cancer].
    Zhang F, Lu YP.
    Zhonghua Nan Ke Xue; 2020 Apr 10; 26(4):364-368. PubMed ID: 33351306
    [Abstract] [Full Text] [Related]

  • 20. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
    Mori K, Mostafaei H, Pradere B, Motlagh RS, Quhal F, Laukhtina E, Schuettfort VM, Abufaraj M, Karakiewicz PI, Kimura T, Egawa S, Shariat SF.
    Int J Clin Oncol; 2020 Nov 10; 25(11):1892-1900. PubMed ID: 32924096
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.